TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics to Report Second Quarter 2022 Financial Results

28 июл 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 июл 2022 17:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 июн 2022 17:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference

02 июн 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

17 май 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

16 май 2022 07:00:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 май 2022 17:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2022 Financial Results

05 май 2022 16:01:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

03 май 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2022 Financial Results

28 апр 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Plan for Chief Financial Officer Transition

20 апр 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 апр 2022 17:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022

06 апр 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

21 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 мар 2022 17:00:00 Источник Nasdaq GlobeNewswire

Travere Prices Upsized $275 Million Convertible Senior Notes Offering

08 мар 2022 21:00:26 Источник Nasdaq GlobeNewswire

Travere Announces Proposed Convertible Senior Notes Offering

08 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at the Barclays Global Healthcare Conference

03 мар 2022 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Recognizes Rare Disease Day 2022 and Raises Awareness for People Living with Rare Disease

28 фев 2022 08:00:02 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

24 фев 2022 16:01:01 Источник Nasdaq GlobeNewswire